To The Moon

$SPDR S&P Biotech ETF ( $Spdr S&P Biotech Etf(XBI)$ )$ $Pfizer ( $Pfizer(PFE)$ )$ $S&P 500(. $S&P 500(.SPX)$ )$ $Dow Jones Industrial Average(. $Dow Jones(.DJI)$ )$As of April 18, 2025, the U.S. stock market is reeling from a volatile week, with the S&P 500 shedding 2.8% on April 17 and the Dow Jones Industrial Average dropping 1,200 points in a single session. Fears of escalating trade tensions and a hawkish Federal Reserve have sparked widespread selling. Yet, amid the chaos, biotech stocks are staging an unexpected rally, driven by breakthrough drug approvals and M&A chatter. Is this a sector to

Healthcare giant $UnitedHealth(UNH)$ obliterated and is on track for its biggest loss in 27 years.Keydata: EPS of $7.20 missing expectations of $7.29, Revenue of $109.6B missing expectations of $111.6B.Why is $UNH down 23%? An amazing buying opportunityQ1 2025 Earnings Report AnalysisCompany OverviewUnitedHealth Group is a globally leading diversified healthcare company, operating primarily through two business segments: UnitedHealthcare (which provides health insurance and benefits services) and Optum (which offers information and technology-supported health services). The company is committed to helping people live healthier lives through innovative healthcare solutions and efficient operating models.Business and Business Model IntroductionUnited

It was roughly about a month ago that Wedbush Securities analyst Dan Ives warned Tesla CEO Elon Musk that patience among his shareholders was “wearing very thin”. It now looks as if it has finally snapped, after Wall Street’s most reliable $Tesla Motors(TSLA)$ bull slashed his price target nearly in half, blaming the polarizing CEO for poisoning the well. Moving forward, Ives said, EV sales for the brand that once hit breakneck speeds will only crawl ahead with percentage gains in the single digit as a result. “Demand destruction for Tesla and brand damage is real,” Ives wrote, “and has morphed into something much more concerning over the past few months.” By cutting his price target to $315 from $550, the Wedbush analyst broke ranks from many Tes

After going throughTiger Post’s “Missed a Rally or Caught up in a Down Trend ”, I had a thought over. Apply the concept of “lesser of the two evils”, my ultimate decision is I rather missed a rally than get caught in a down trend. Missing out (to me) implies: Due to “ill timing or whatever reason/s”, no investment has been made before market took off. It also means no monies were lost in the process, albeit no gain also. Personally, I think there is no right or wrong answer to the situational scenario. But is it true that there are only two options available?”? I beg to differ. I researched further on the other option “caught in a down trend” that I did not select. And I found a stop-loss solution article (see below). Gist Of The Post: Sitting on losses is never a good strategy. This is

On Thursday, the Federal Reserve raised interest rates by 25 basis points as expected, Chairman Bauer left the door open for future rate hikes, investors digested a fresh batch of earnings, and Microsoft led technology shares down amid a mix of bearish and bearish news.A 14-day winning streak on Thursday would tie the longest winning streak since June 1897, set about a year after the Dow was founded in May 1896.Social media leader Meta's second-quarter revenue rose 11 percent, beating market expectations. It also gave an encouraging third-quarter forecast and said its new short-form video feature Reels is successfully attracting advertisers, sending its shares up nearly 7 percent in premarket trading on Thursday.Intel will release its earnings report after the closing bell on Thursday, and

1. $Tilray Inc.(TLRY)$ +14.88%: reported a smaller loss and higher revenueCannabis company Tilray Brands saw its 15% rise after it reported a smaller loss in the fourth quarter compared to the same period in the previous year.The company's revenue also experienced a significant increase, rising 20% to $184.2 million, surpassing the $153.3 million generated in the same quarter of the prior year and exceeding analysts' expectations.Adjusted EPS: $0 vs. -$0.043Revenue: $184.2 mln vs. $152.77 mlnLooking ahead to fiscal year 2024, Tilray forecasts adjusted EBITDA of $68 million to $78 million, indicating growth of 11% to 27% over fiscal year 2023.Tilray, a Canadian company, has been strategically positioning itself to become a major player in the

One of the most popular buzzwords in investing today is “compounders.” Growth-oriented investors loo